Navigation Links
Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
Date:6/24/2013

HAYWARD, Calif., June 24, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with autoimmune disorders, today announced it has initiated the BRIGHT-SC Phase 2 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of IgA nephropathy. IgA nephropathy is a chronic autoimmune renal disease characterized by proteinuria and progression to end stage renal disease.

BRIGHT-SC is a multicenter, placebo-controlled, double-blind, Phase 2 clinical study that is expected to enroll at least 48 patients from Asia Pacific geographies. Patients will be randomized into one active treatment arm or one placebo arm. The primary endpoint of the study will be a reduction in proteinuria at 32 weeks. The Company plans to conduct an interim analysis of proteinuria after patients have completed 8 weeks of therapy. Secondary endpoints will include the effects of blisibimod on estimated Glomerular Filtration Rate (eGFR), plasma B cells, and other biomarkers of kidney disease.

In May, the company met with the US FDA to discuss the future of the IgA nephropathy development plan. "We are encouraged by the outcome of our pre-Investigational New Drug meeting with the FDA. The use of proteinuria as a primary endpoint in studies of IgA nephropathy was well received by the agency," said Paula Adams, PhD, Anthera's Vice President of Regulatory Affairs and Compliance. "Data from the BRIGHT-SC study design will be helpful in our efforts to obtain an accelerated approval for blisibimod in this potential orphan indication." In the coming weeks the Company will be meeting with the Japanese Pharmaceutical Medical Devices Agency to explore development strategies in Japan.'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... strategic transaction processSAN DIEGO, May 7 ADVENTRX ... today announced results from its bioequivalence study of ... have comparable overall safety as Taxotere(R), the reference ... severe toxicities. However, pharmacokinetic equivalence, the primary ...
... is to Enhance Patient Safety and Reduce Health Care ... will join in a pilot program, contributing data on ... the data collected, it will be possible to identify ... patient safety while reducing overall costs to the health ...
Cached Medicine Technology:ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3
(Date:7/13/2014)... best treatment and variations in the quality of care ... cancer patients still varies widely between regions within Europe, ... European adults to date, published in The Lancet ... survival for most cancers of the blood has increased ... approval of new targeted drugs in the early 2000s ...
(Date:7/13/2014)... Intraocular Lens (IOL) Market: Global Industry ... 2019 , Intraocular lens (IOL) is inserted in the ... The lenses are inserted inside the eye, after removal ... replaces the focusing power of natural lens. The pseudophakic ... deliver the light focusing function which was originally undertaken ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
(Date:7/13/2014)... The North American water storage systems market is estimated to ... 2018, at a CAGR of 21.0%, from 2013 to 2018. ... pace in North America. The U.S. is experiencing high growth ... storage and collection, and the increased spending on modernization and ... healthy rate in Canada, and is rising at a rapid ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... 11 (HealthDay News) -- Parkinson,s disease patients who receive care ... break a hip or need nursing-home placement than those treated ... American researchers looked at the medical records of all ... Between that time and 2005, 68 percent of the patients ...
... drugs as a first-line treatment for people with tuberculosis (TB) ... not been well understood. Now, researchers have discovered a key ... TB therapy. The finding potentially paves the way for the ... an infected individual even more rapidly. The study was supported ...
... THURSDAY, Aug. 11 (HealthDay News) -- What do a ... A lot more than you might expect, new research ... aquatic reptile with its embryo offers the first evidence ... that they may have had a social structure similar ...
... August 11, 2011) According to a study ... the American Society of Hematology (ASH), researchers have ... that releases stem cells from the bone marrow into the ... risk for later development of abnormalities involving loss or gains ...
... , THURSDAY, Aug. 11 (HealthDay News) -- American women ... those born in 1910 or 1960, according to researchers who analyzed ... 1935 had an average of three children per woman, compared with ... for those born in 1960, their study found. Of the ...
... 11 (HealthDay News) -- Like humans, chimpanzees are born ... to track the development of three chimpanzees, brains from ... areas of the brain that play an important role ... and creativity are immature in both chimps and humans, ...
Cached Medicine News:Health News:Parkinson's Patients May Fare Better in Neurologist's Care 2Health News:Prehistoric Water Reptile's Social Life Similar to Dolphins: Study 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Women Born After Great Depression Had More Children, Study Finds 2
... CELL-DYN 1800 is the latest 3-part differential ... since the founding of the CELL-DYN line. ... data management capabilities, the CELL-DYN 1800 meets ... CELL-DYN 1800 is smaller than its predecessors ...
... Net Point-of-Care Data Networking is hospital ... of data networking. In seconds, point ... be transferred from nursing stations throughout ... is instantly available to laboratory staff ...
... EarlyDetect® Menopause Test is a one ... menopause has occured. This test can ... follicle-stimulating hormone (FSH), which indicates whether ... simple to use and in a ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
Medicine Products: